BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding BioAtla, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 67 | 43 | −24 |
| Shares | 24.0M | 13.7M | −10.3M (−42.9%) |
| Value | $14.2M | $4.77M | −$9.43M (−66.4%) |
New holders (4)
Institutions that held BioAtla, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 76,324 | $26.5K | 0.00% |
| Simplex Trading, LLC | 9,463 | $3.00K | 0.00% |
| Flaharty Asset Management, LLC | 4,150 | $1.44K | 0.00% |
| Barclays PLC | 6 | $2 | 0.00% |
Sold out (28)
Institutions that held BioAtla, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.